StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Raymond James Resumes Audentes Therapeutics (BOLD) at Outperform
July 29, 2019 6:58 AM
Raymond James analyst Steven Seedhouse resumes coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
New Coverage